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Abstract 
Liposomes have been used as carriers of various materials and as tools for gene transfer: for the latter purpose, positively charged 
liposomes are usually used. To evaluate the stability in the presence of serum and the in vivo behavior of such liposomes as well as those 
aspects of neutral and negatively charged liposomes, we investigated liposomal agglutinability in the presence of serum, serum protein 
binding to these liposomes, and real-time liposomal trafficking by a non-invasive method using positron emission tomography (PET). 
Liposomes composed of dipalmitoylphosphatidylcholine, cholesterol without or with charged lipid were prepared in the presence of 
mannitol, and the turbidity change in the presence of serum was determined. Turbidity increase was not observed for so-called 
long-circulating liposomes, i.e., liposomes modified with glucuronic acid or with poly(ethylene glycol), or for negatively charged 
liposomes containing dicetyl phosphate (DCP), phosphatidylglycerol, or phosphatidylserine. On the contrary, a significant turbidity 
increase was observed when positively charged liposomes modified with stearylamine, stearyltrimethylammmonium chloride or 
1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl bromide (DMRIE), which is known as a component of liposomes for gene transfer, 
were used. These liposomes were found to have bound a high amount of serum proteins after separation of unbound serum proteins by 
use of a spin column. The liposomal trafficking in vivo was determined for three kinds of liposomes, i.e., liposomes with DMRIE, those 
with DCP, and those without charged lipids. These liposomes were prepared in the presence of 2-[“Flfluoro-2-deoxy-D-glucose 
([2- ‘*F]FDG), and the [2-“F]FDG-labeled liposomes were administered to mice to perform PET scans. Positively charged liposomes 
containing DMRIE showed high accumulation in the liver compared with neutral and negatively charged liposomes. Since DMRIE-lipo- 
somes tended to aggregate in the presence of serum, and to be associated with serum protein, these characters may lead to the high uptake 
of DMRIE-liposomes by the liver. 
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1. Introduction 
Liposomes can encapsulate various materials and have 
been used as drug carriers. Many previous studies have 
demonstrated the enhanced efficacy of encapsulated drugs 
Abbreviations: DCP, dicetyl phosphate; DMRIE, 1,2-dimyristyl- 
oxypropyl-3-dimethylhydroxyethyl bromide; DPPC, dipalmitoylphospha- 
tidylcholine; DPPG, dipalmitoylphosphatidylglycerol; FBS, fetal bovine 
serum: [2- “F]FDG, 2-[ ‘“Flfluoro-2-deoxy-Bglucose; PBS, phosphate- 
buffered saline; PEG-PE, poly(ethylene glycol)phosphatidylethanolamine; 
PET, positron emission tomography; PGlc, palmityl-D-glucoside; PGlcUA, 
palmityl-Bglucuronide; PS, phosphatidylserine; SA, stearylamine; STAC, 
stearyltrimethylammmonium chloride. 
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and the reduction of the side effects of drugs so entrapped 
[ 1,2]. The clearance of liposomes from the circulation is 
known to occur mainly by the trapping of liposomes in the 
reticuloendothelial system, such as liver and spleen, and to 
be greatly affected by liposomal size, charge, and lipid 
composition. In the field of drug delivery systems, neutral 
or negatively charged Iiposomes are commonly used. 
On the other hand, Iiposomes are also being explored as 
suitable carriers of gene in the field of gene therapy. Some 
cationic liposomes have been used as a tool of gene 
transfer [3,4]. For transferring genes in vivo, DNA-lipo- 
some complexes have been revealed to be as useful as 
replication-defective retroviral vectors, though the precise 
biodistribution of these Iiposomes has not been examined 
[5]. Furthermore, gene transfer via liposomes can avoid the 
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incorporation of DNA into the host genome; this character 
is useful for the purpose of transient expression of gene 
products, such as for suppression of inflammatory dis- 
eases. Liposomal DNA can be administered via vein, 
artery, peritoneal cavity, airway, and so on. The intra- 
venous route is attractive if the target can be controlled. 
The trafficking of such positively charged liposomes in 
vivo has, however, not been examined precisely. 
In the present study we investigated the stability in 
serum of liposomes containing various modifiers including 
those for gene transfer, by means of liposomal agglutin- 
ability and serum protein binding to these liposomes. 
Furthermore, the real-time trafficking of three kinds of 
liposomes with different charges was determined by use of 
positron emission tomography (PET); the method was 
recently established by us to determine the liposomal 
trafficking in vivo non-invasively [6]. The present study 
indicates that positively charged liposomes are easily 
trapped by liver, since they tend to aggregate in the 
presence of serum and to bind serum proteins that may 
opsonize the liposomes. The data suggest that some modi- 
fication of liposomes might be necessary for systemic 
injection of cationic liposomes when the target is not the 
liver, although differential trafficking may occur when 
DNA is bound to these liposomes. 
2. Materials and methods 
2.1. Materials 
1,2-Dimyristyloxypropyl-3-dimethylhydroxyethyl bro- 
mide (DMRIE) was synthesized according to the method 
described earlier [7]. Palmityl-D-glucuronide (PGlcUA) was 
synthesized as previously described [8], and palmityl-o- 
glucoside (PGlc) was synthesized according to a similar 
procedures. Poly(ethylene glycol)-conjugated dis- 
tearoylphosphatidylethanolamine was prepared as de- 
scribed before [9], with PEG having an average molecular 
weight of 2000. Dipalmitoylphosphatidylcholine (DPPC) 
and dipalmitoylphosphatidylglycerol (DPPG) were the 
products of Nippon Fine Chemical Co. (Hyogo, Japan). 
Dicetyl phosphate (DCP), stearylamine (SA), and choles- 
terol were purchased from Sigma (St. Louis, MO). 
Stearyltrimethylammonium chloride (STAC) was obtained 
from Nacalai Tesque Inc. (Kyoto, Japan). BioGel A-15m 
(200-400 mesh) was obtained from Bio-Rad Laboratories, 
Inc. (Tokyo, Japan); and fetal bovine serum (FBS), from 
JRH Biosciences (Lenexa, KS). 
2.2. Preparation of liposomes 
Liposomes were prepared as follows: DPPC and choles- 
terol (10: 10 in a molar ratio), or DPPC, cholesterol, and 
modifying lipids (uncharged PGlc or various charged lipids) 
in a molar ratio of 10: 10: I were dissolved in 
chloroform/methanol, dried under reduced pressure, and 
stored in vacua for at least 1 h. After hydration of the thin 
lipid film with 0.3 M mannitol (containing IO mM DPPC), 
the resulting liposomal solution was frozen in liquid nitro- 
gen and thawed for three cycles. Then the liposomes were 
extruded through a polycarbonate membrane filter having 
400-nm, 200-nm, and lOO-nm pores (Nuclepore) three 
times for each pore size. 
Liposomes for the PET analysis were prepared as de- 
scribed previously [6]. In brief, DPPC and cholesterol with 
DMRIE or DCP (IO: 10: 1 as a molar ratio), or without 
charged lipid were dissolved in chloroform and dried 
under reduced pressure. After hydration of the thin lipid 
film with 1.0 ml of 0.45 M sodium gluconate, the resulting 
liposomal solution was mixed with 2.0 ml of [2- ” F]FDG 
solution; and three cycles of freeze-thawing using liquid 
nitrogen was performed for trapping of the radioactive 
chemical by the liposomes. Then the liposomes were ex- 
truded three times through a polycarbonate membrane filer 
having a lOO-nm pore size. To remove the untrapped 
[2-18F]FDG, We diluted the liposomes with saline and 
centrifuged them at 180000 X g for 20 min. 
2.3. Assay of liposomal aggregation in the presence of 
serum 
Liposomes prepared in 0.3 M mannitol were incubated 
in PBS or in 50% FBS for 30 min at 37°C (final concentra- 
tion of liposomes was 0.5 mM as DPPC). Liposomes were 
also incubated for a week at 4°C to determine their stabil- 
ity during storage. The turbidity of the liposomal solution 
was determined at 450 nm, and relative turbidity compared 
with that in mannitol was calculated. 
2.4. Determination of serum protein binding to liposomes 
100 ~1 of liposomes prepared in 0.3 M mannitol was 
incubated with 100 ~1 of FBS at 37°C for 30 min. Then a 
lOO-~1 aliquot of the reaction mixture was applied to the 
spin column, which was prepared according to a published 
method [ 101 that was slightly modified as follows: I-ml 
tuberculin syringes plugged with 30 mg of glass wool were 
filled with BioGel A- 15m equilibrated with PBS and 
packed by centrifugation at 800 rpm for 30 s. The column 
was eluted with every lOO-~1 volumes of PBS by a 
centrifugation at 500 rpm for 30 s. Complete separation of 
liposomes from free serum proteins was confirmed by 
separate elution of liposomes and FBS. The liposomal 
fraction, i.e., the void volume, was collected; and the 
amounts of protein and phospholipids were determined 
with a protein assay kit (Bio-Rad) and by phospholipid 
phosphorus assay, respectively. 
2.5. PET analysis of liposomal traflcking 
Seven-week-old Balb/c male mice (Japan SLC Inc.) 
weighing 25-30 g were anesthetized with sodium pento- 
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barbital and injected into a tail vein with positron-labeled 
liposomes. The amount administered was 9 pmol as total 
lipids, and about 1.85 MBq. The emission scan was started 
immediately after injection and performed for 120 min 
with an animal PET camera (Hamamatsu Photonics, HSR- 
2000) having an effective slice aperture of 3.25 mm and 
resolution of 2.7 mm. Transmission scans were obtained 
by use of an 18.5 MBq ‘*Ge/Ga ring source for attenua- 
tion correction before the liposomal injection. The radioac- 
tivity in the form of coincident gamma photons was mea- 
sured and converted to Bq/cm’ of tissue volume by 
calibration after correction for decay and attenuation. A 
time-activity curve was obtained from the mean pixel 
radioactivity in the region of interest (ROI) of the PET 
images. 
3. Results 
3.1. Aggregation of and serum protein binding to lipo- 
somes with different charges 
Hepatic and splenic uptake of liposomes depends on 
liposomal size. In fact, larger sized liposomes are more 
easily taken up by liver than the smaller ones. Although 
the liposomes used here were sized by extrusion method, if 
the aggregation of liposomes would occur in the presence 
of serum, it might cause liver trapping of the liposomes. 
Therefore, we determined the agglutinability of the lipo- 
somes containing variously charged lipids. As shown in 
Fig. la, neutral liposomes tended to make aggregates in 
PBS, whereas the other liposomes did not do so in the 
PBS. After a week of incubation at 4”C, neutral liposomes 
formed a visible precipitate which could be easily resus- 
pended by mechanical shaking. 
The agglutinability of positively charged liposomes 
markedly increased in the presence of serum, as shown in 
Fig. lb. Neutral and negatively charged liposomes also 
showed enhanced agglutinability in the presence of serum. 
In contrast, glucuronic acid- or PEG-modified liposomes 
did not aggregate in the presence of serum. 
The binding of serum proteins, so-called opsonins, to 
the liposomal surface is another important factor for lipo- 
somal uptake by the liver and spleen. Liposomes having a 
long-circulating life are known to associate with a small 
amount of serum proteins, whereas liposomes associated 
with a large amount of serum proteins are easily trapped 
by the liver and spleen [l 11. Thus, we determined the 
serum protein binding to the liposomes by the spin column 
procedure for separating protein-bound liposomes from 
free serum proteins. As shown in Fig. 2, serum protein 
binding was marked when positively charged liposomes 
were incubated in FBS. This characteristic may be respon- 
sible for the high agglutination of positively charged lipo- 
somes in the presence of serum. 
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Fig. I. Liposomal agglutinability in the presence and absence of serum. 
(a) Liposomes composed of DPPC, cholesterol, and modifying lipids 
(IO: IO:1 as a molar ratio) as indicated in the figure were incubated at 4°C 
for I week (open bars) or at 37°C for 30 min (closed bars) in PBS. The 
relative turbidity at 450 nm against that in 0.3 M  mannitol solution is 
shown. (b) Similar procedures as used in ‘a’ were performed except that 
the liposomes were incubated at 37°C for 30 min in the presence of 50% 
FBS. The net charge of l iposomes is shown in parentheses. 
3.2. Traficking of l iposomes with diferent charges deter- 
mined by PET 
Next we determined the trafficking of three kinds of 
differently charged liposomes. Liposomes containing DM- 
RIE (positively charged liposomes) or DCP (negatively 
charged liposomes) as well as those without charged lipids 
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Fig. 2. Serum protein binding to l iposomes with various compositions. 
Liposomes composed of DPPC, cholesterol, and modifying lipids (IO: IO: I 
as a molar ratio) as indicated in the figure were incubated at 37°C for 30 
min in the presence of 50% FBS. Then the spin column procedure was 
performed for separating the liposomal fraction from unbound serum 
proteins as described in Section 2. The amount of protein and DPPC 
content in the liposomal fraction were determined and expressed as g 
protein bound per mmol DPPC. 
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Fig. 4. PET determination of hepatic and splenic accumulation of lipo- 
somes with various charges. Liposomal trafficking was determined by 
PET as described in Section 2 and in the legend of Fig. 3. Time-activity 
curves of “F in liver (a) and spleen (b) were obtained after injection of 
l iposomes modified with DMRIE (0). with DCP (0) or without charged 
lipid ( q ). 
were positron labeled with [2-“FIFDG. Then the PET 
analysis of liposomal trafficking was performed. Fig. 3 
shows the biodistribution of these liposomes in mice dur- 
ing the period of 30 to 60 min after injection. The PET 
images show the coronal planes of liver and spleen. Slices 
8-11 correspond to the liver location; and the right side of 
slices 6 and 7, to the spleen. Intense accumulation of 
DMRIE-liposomes shown in the 8-10th slices indicates 
the liver accumulation of these liposomes. On the contrary, 
neutral and negatively charged liposomes did not accumu- 
late in the liver compared with the positively charged ones. 
Accumulations of liposomes in lungs, kidneys and other 
residual tissues were not observed by PET imaging. Lipo- 
somal FDG was shown not to leak out during a 2-h 
incubation in fetal bovine serum [6], suggesting that the 
images obtained here indicate the trafficking of liposomes 
and not any free [2-“F]FDG released from the liposomes. 
Fig. 4 shows the time-activity curves of liposomal 
accumulation in the liver and spleen. The liver accumula- 
tion of DMRIE-liposomes was different from that of neu- 
tral and DCP-liposomes: DMRIE-liposomes accumulated 
to a high level time-dependently in the liver, up to 40 min, 
whereas the other liposomes showed no such increase in 
the liver accumulation. Liposomal accumulation in spleen 
was similar among the three types of liposomes, although 
the highest accumulation was observed when DMRIE-lipo- 
somes were injected. 
4. Discussion 
Liposomes have been used as drug carriers in the field 
of drug delivery system technology, since they consist of 
non-toxic biomolecules and they can encapsulate both 
hydrophilic and hydrophobic materials. Clearance and 
biodistribution of liposomes of various size, charge, and 
composition have been determined; however, real-time 
examination by a non-invasive method has not been done 
much. We recently developed such a method by use of 
positron emission tomography [6]. This method might be 
useful for evaluating liposomes as drug carriers. Therefore, 
we determined the trafficking of liposomes with various 
compositions in relationship to the their agglutinability in 
the presence of serum and to the serum protein binding to 
them. 
With respect to liposomal agglutinability in PBS, neu- 
tral liposomes tended to make aggregates, suggesting that 
charge repulsion prevents liposomal aggregation. Interest- 
ingly, more marked aggregation of positively charged lipo- 
somes was observed in the presence of FBS. This evidence 
may relate to the binding of serum proteins to the liposo- 
ma1 surface, as was shown in Fig. 2. 
The PET study showed that positively charged lipo- 
somes tend to accumulate in the liver and spleen to a much 
greater extent compared with neutral or anionic liposomes. 
Although the reason for this high accumulation in the 
reticuloendothelial system (RES) of the positively charged 
liposomes is not fully understood, both aggregation of 
liposomes in the presence of serum and opsonization of 
them by serum proteins may cause RES trapping of these 
liposomes. In fact, RES-avoiding liposomes were reported 
to be associated with fewer serum proteins than liposomes 
with short half-lives in the bloodstream [I 11. Our present 
result also showed that two types of long-circulating lipo- 
somes, i.e., PEG- and glucuronide-modified liposomes, 
neither aggregated in the presence of serum nor bound a 
high amount of serum proteins. As positively charged 
liposomes were reported to activate the complement sys- 
tem via the alternative pathway [12], such liposomes might 
not be suitable as a drug carrier when the target is not the 
RES. 
The PET analysis presented here also indicated that the 
hepatic trapping of liposomes reached plateau at about 40 
min after injection, while splenic trapping increased time- 
dependently more slowly to its maximum. This tendency 
well correlates with reported evidence that liposomal trap- 
ping in RES was saturable at first in the liver and then in 
the spleen [ 131. 
By the way, recent progress in the field of gene transfer 
indicates that cationic liposomes are useful tools for deliv- 
ering genes into cells. 2,3-Dioleyloxypropyl- 1 trimethyl- 
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ammonium bromide (DOTMA), being the trademark Lipo- 
fectin, has already been commercialized [14]. After devel- 
opment of Lipofectin, 3p-(N-(N’,N’-dimethylaminoeth- 
ane)carbamoyl)cholesterol (DC-chol) [ 151 and DMRIE [7] 
were developed for enhancing transfer efficiency of genes. 
In this study we used DMRIE as one of the modifiers of 
liposomes, since the biodistribution data on these lipo- 
somes may be helpful for actual use of these liposomes in 
the field of gene transfer. 
Although the positively charged liposomes are not fa- 
vorable as a drug carrier, as shown in the present study, 
cationic liposomes might have potential as a tool for gene 
transfer. Since the actual trafficking of cationic liposome- 
DNA complexes might be different from that of positively 
charged liposomes without DNA, the DNA could reduce 
the positive charge. Furthermore, although the complex 
has large size, it is possible that the size is smaller than the 
aggregation form of the positively charged liposomes with- 
out DNA in the serum. We are now planning to examine 
these possibilities. In the present study, we used DPPC as 
a main component of liposomes. Dioleoylphos- 
phatidylethanolamine, however, is usually used as a main 
component of liposomes for gene transfer. This difference 
may also be possible to affect the liposomal trafficking. 
We used only DMRIE-containing liposomes in this experi- 
ment. To evaluate the trafficking of DOTMA- and DC- 
chol-containing liposomes may also be interesting. 
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